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Misoprostol is a synthetic prostaglandin currently employed to induce labor. Association with illegal abortion has been
reported; however, neonatal outcome and morbidity after a failed attempt of abortion has not been described.
Objectives: To report the association between misoprostol self-medication and preterm labor and to assess perinatal risk
factors, morbidity and early outcomes.
Methods: We conducted a prospective study of all very low birth weight (VLBW) infants delivered in Hospital Fernando
Fonseca, during a 5-year period. VLBW infants were assigned to misoprostol group (MG) when preterm delivery was
attributed to misoprostol and matched with newborns with similar gestational age, birth- weight, and gender.
Results: During the study period 311 VLBW infants were born. Nineteen belonged to misoprostol group (MG) and 58 were
selected for controls. Mothers from MG were significantly younger (21.5 vs 27.5, p=0.001) and from African origin (74 vs
31%, p=0.006), had significantly less prenatal care (21 vs 67%, p=0.000), less antenatal steroids (5 vs 50%, p=0.001),
and were delivered less often by C-section (11 vs 60%, p=0,000). MG infants had significantly higher rates of patent duc-
tus arteriosus (58 vs 29%, p=0.031) and chronic lung disease (47 vs 14%, p= 0.026). Mortality rate at 3 months was sim-
ilar in both groups, but the incidence of abnormal neurodevelopment at 1 year of age was significantly higher in the MG
(50 vs 16%, p= 0.02).
Comments: The worse outcome of MG infants seems to be determined by prenatal, natal, and postnatal factors and we
believe that misoprostol is probably a significant adjuvant cofactor.
Misoprostol is a synthetic E1 prostaglandinapproved to treat peptic ulcer disease (Goldberg,Greenberg, & Darney, 2001). It has also an effecton myometrical contractility and cervical ripening
(Sheepers, Van Erp, & Van den Berg, 1998). Although its use
has not been approved during pregnancy, unlicensed use to
induce labor is increasingly common.
The first report of misoprostol use as an abortifacient
came from Brazil in 1986 (Costa, 1998). By 1990, about
70% of women hospitalized in Brazil with abortion-related
diagnoses referred to the use of this drug. Abortion remains
illegal in Portugal as in many other predominately Catholic
nations. Over the past decade, we have seen a rise in the
phenomenon of live born infants in our intensive care nurs-
ery after attempted abortion very late in pregnancy. These
women appear unaware that inducing labor in the third
trimester will result in a premature but live born infant. To
date the consequences of the illegal use of misoprostol early
in the third trimester of pregnancy have not been reported.
Our purpose is to report that self-medication with
Misoprostol can be a cause of viable very low birth weight
(VLBW) newborns. Because we have seen so many of these
infants, we are able to also assess and report perinatal risk
factors, neonatal morbidity, and early outcomes.
Methods
We conducted a prospective analysis, with a matched
case-control design, of all VLBW infants admitted to the
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MG progressively increased, from 4 in 1997, to 8 in the first
half of 2001.
Mothers from the MG were more likely to be younger
(21.5±4.5 vs 27.5±7.1, p=0.001) and born outside of
Portugal (74% vs 31%, p=0.006). Table 1 shows maternal
characteristics. Comparing perinatal data (see Table 2),
infants from the MG had significant less prenatal care during
pregnancy (21% vs 67%, p=0.000), less antenatal steroids
(5% vs 50%, p=0.001), and were delivered less often by
cesarean section (11% vs 60%, p=0.000).
Comparing neonatal morbidity (see Table 3), the MG had
significantly higher rates of patent ductus arteriosus (58% vs
29%, p=0.031) and chronic lung disease (47% vs 14%
p=0.026). There were no differences between groups con-
cerning respiratory disease syndrome (RDS), sepsis, intra-
ventricular hemorrhage (IVH), retinopathy of prematurity
(ROP), or necrotizing enterocolitis (NEC).
The mortality rate at 3 months or NICU discharge was
similar in both groups (21% vs 26%, p=ns). In the MG, the
incidence of abnormal neurodevelopmental at 1 year of age
was significantly higher. The most frequent disability was
cerebral palsy (29% vs 3%, p=0.015).
Discussion
Misoprostol used in conjunction with either mifepristone
or methotrexate is highly effective for medical abortion
(Norman, Thong, & Baired, 1991). However, when used
alone to induce complete abortion, its effectiveness has been
reported as lower (Ngai, Tang, Chang, & Ho, 2000). The
uterus becomes more sensitive to misoprostol with increas-
ing gestational age. Therefore, in the third trimester, small
doses of misoprostol can be effective for inducing vaginal
delivery within 24 hours (Creinin & Vittinghoff, 1994).
The self-administration of misoprostol in the late second
or early third trimester of pregnancy can result in the deliv-
Since 1999, American women have been provided an
alternative option for treatment of unwanted babies. The
infant safe haven laws allow women or their legal guardians
to safely relinquish their infants to a place where medical
care will be provided and a safe placement found. To date
46 states have enacted such laws. These laws were initiat-
ed as part of the federal Promoting Safe and Stable Families
Amendments of 2001 (Public Law 107-133), which amend-
ed the Family Preservation Services to allow States to sup-
port infant safe haven programs. These babies often come
from women in the same crisis as those described in the
accompanying article from Portugal; women who are in a
state of denial about being pregnant or are afraid to tell any-
one. Their desperation contributes to irrational acts that
prior to this law led to infants being disposed of in dump-
sters or public toilets and left to die. 
According to the National Conference of State
Legislatures (NCSL), in 1998 there were 105 public aban-
donments and 31,000 babies left in hospitals (Affholter,
2000). And formerly, if caught, women were prosecuted for
child neglect, abuse, or murder. Now the mother or moth-
er’s representative may drop off the baby at any designat-
ed safe haven, such as a fire station or hospital emergency
room. She is allowed to remain anonymous and no arrest or
prosecution takes place. Personnel at the safe haven bring
the child for an immediate medical exam, and then the local
child protective agency is contacted and the child is placed
in a temporary foster home. The laws allow procedures for
a woman to change her mind or for a nonrelinquishing
father to attempt custody. If the child is not reclaimed, ter-
mination of parental rights and adoption usually follow. This
program has proven very successful. The emphasis now is
to disseminate information to high school students and
young adults about the program’s existence.
Reference
Affholter, P. (2000, May/June). Safe havens for abandoned babies.
State Notes: Topics of Legislative Interest. Located on
February 15, 2005 at http://www.senate.michigan.gov/
sfa/Publications/Notes/2000Notes/NotesMayJun00Affholter.
PDF
neonatal intensive care unit (NICU) of the Hospital Fernando
Fonseca, Amadora, Portugal, from June 1996 to July 2001.
Data were collected from interviewing the mothers and from
infant charts.
VLBW infants born from pregnant women who had taken
misoprostol, either orally or vaginally, immediately in the 24-
48 hours preceding labor, were assigned to the Misoprostol
Group (MG). In these cases, without any other risk of pre-
maturity, preterm labor was attributed to misoprostol. These
infants were matched with VLBW with similar gestational
age, birth-weight, and gender who served as controls
(Controls). Infants with major congenital malformations were
excluded.
Gestational age was based on the date of the last men-
strual period, early prenatal ultrasound, obstetric examina-
tion, and/or on the New Ballard scoring system (Donovan et
al., 1995). The neurodevelopmental impairment was
assessed by physical examination and Griffith’s mental
developmental scale. Cerebral palsy (CP), blindness or stra-
bismus and sensorineural deafness rates were determined.
Cerebral palsy was defined as a group of nonprogressive
motor impairment syndromes secondary to lesions of brain
arising in the early stages of development (Muntch,
Alberman, Hagberg, Kodama, & Perat, 1992).
SPSS for Windows 10.0 was used for statistical analysis.
Differences between groups were compared using the Mann-
Whitney test for continuous variables and a Fisher´s exact
test for categorical variables. P values <0.05 were considered
statistically significant.
Results
During the 5-year study period, 311 VLBW infants were
admitted to our unit. Nineteen (6%) belonged to the miso-
prostol group (MG) and 58 were matched for controls.
Throughout this period, the proportion of newborns in the
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ery of a viable VLBW infant and this, to our knowledge, has
not yet been reported. We are particularly concerned by the
fact that the use of this drug to induce abortion is steadily
increasing through a 5-year time span and in some social
groups.
Preterm labor is the single most important cause of peri-
natal mortality and it is also a major determinant of long-
term morbidity (Stevenson & Wright, 1998). In our neonatal
intensive care unit in Lisbon, Portugal, we found a surpris-
ingly high proportion of VLBW infants born as a conse-
quence of misoprostol, and this is a huge problem that must
be considered. In fact, we observed major differences in the
obstetrical care of these infants. Mothers from the MG fre-
quently had received no prenatal care and, as expected, pro-
cedures such as caesarean section and antenatal steroids
were also different.
Antenatal corticosteroid therapy for women at risk for
preterm delivery improves survival in their infants and
reduces the risk for RDS, chronic lung disease (CLD), IVH
and mortality (NIH, 1995). Antenatal steroid use ranges from
72% in the Vermont-Oxford study (Horbar, Badger,
Carpenter, Fanaroff, 2002) to 77.6% in the National
Portuguese Database (Grupo do Registo Nacional, 2002).
We found only 5% of the MG infants had received steroids,
probably related to the non-existence of obstetric care in
these infants. Although we did not observe a corresponding
increase in the frequency of RDS, all infants from the MG
required surfactant and intermittent positive pressure venti-
lation (IPPV), which could also reflect the increased severity
of the RDS.
The incidence of patent ductus arteriosus (PDA) was also
remarkably higher than expected. It was 20% in the National
Portuguese Database (Grupo do Registo Nacional, 2002).
We speculate that the prostanglandin nature of Misoprostol
might explain this difference. PDA has been implicated as
the cause of chronic lung disease (Farrell & Fiascone, 1997).
In our study, chronic lung disease reached 47% of surviving
MG babies, a surprisingly higher frequency compared to the
results referred in the Vermont-Oxford Trial and in the
Portuguese National Database. Some authors have suggest-
ed that the prophylactic use of indomethacin (antagonist of
prostaglandins) reduces the incidence of CLD and IVH
(Murphy, Hope, & Johnson, 1997). We ponder whether pro-
phylactic indomethacin should be used in all babies exposed
to illegal misoprostol?
Cerebral palsy (CP) is the most frequent neurological
sequelae of VLBW infants, ranging from 8% to 11% (Murphy
et al, 1997). In our study, 7 of the surviving infants from the
MG (50%) presented neurodevelopmental disabilities, 29% of
which were CP. We cannot identify an individual factor that
explains this high frequency, but among the very preterm
babies, the coexistence of several risk factors for cerebral
palsy may be more important than an individual factor. PDA
and absence of antenatal corticosteroid exposure have been
associated with an increased risk of CP (Murphy et al., 1997;
Gray, Jones & O’Callaghan, 2001), factors that were signifi-
cantly different between our groups. Also, CLD has been
directly related to most other morbidities, such as neurode-
velopment delay (Kaempf, Campbell & Sklar, 2002).
However, a reduction in the rate of CP in very preterm babies
probably requires an integrated approach to management
throughout the antenatal, intrapartum and neonatal periods.
Conclusions
There were major differences between groups. The worse
outcome of MG infants seems to be determined by less pre-
natal care, less antenatal steroids prescribed, and signifi-
cantly more frequent PDA and CLD. We believe that although
differences in obstetric care may play a role in this worse out-
come, misoprostrol was, probably, a significant adjuvant
cofactor. Here in Portugal, and perhaps elsewhere, we feel
educational programs must be promoted in order to prevent
the use of misoprostol in pregnancy, especially beyond the
gestational ages of viability.
Table 1. Maternal Characteristics
Sociodemographic Data
Maternal age (yr± SD)
Of African descent (%)
Maternal years of schooling (yr± SD)
Misoprostol
(n =19)
21.5 ± 4.5
74 (14/19)
8.2 ± 2.2
Controls
(n = 58)
27.5 ± 7.1
31 (18/51)
9.3 ± 3.7
P
0.001
0.006
0.528
Table 2. Perinatal Data
Perinatal Data
Prenatal care %
Antenatal steroids %
Cesarean section %
Gestational age, mean (SD)
Birthweight, mean (SD) g
Male %
Misoprostol
(n = 19)
21 (4/19)
5 (1/19)
11 (2/19)
27.3 ± 1,8
966 ± 216
63 (12/19)
Controls
(n = 58)
67 (39/58)
50 (29/58)
60 (35/58)
27.8  2,1
1018 ± 238
57 (33/58)
P
0.000
0.001
0.000
0.227
0.269
0.790
Note: Data expressed as a mean ± SD or percentage.
Table 3. Neonatal Morbidity
Neonatal Morbidity
Respiratory distress syndrome %
Patent ductus arteriosus %
Sepsis %
Necrotizing enterocolitis (grade >1) %
Intraventricular hemorrhage (grade >1)
Periventricular leucomalacia %
Retinopathy of prematurity (grade >1)
Chronic lung disease %
Misoprostol
(n = 19)
100 (19/19)
58 (11/19)
63 (12/19)
0 (0/19)
26 (5/19)
27 (4/15)
33 (5/15)
47 (7/15)
Controls
(n = 58)
85(49/58)
29(17/58)
52 (30/58)
3 (2/58)
24 (14/58)
9 (4/43)
12 (5/43)
14(6/43)
p
0.102
0.031
0.436
1.000
1.000
0.185
0.106
0.026
Table 4. Outcome
Outcome Data
Deaths 3 months
Abnormal neurodevelopment
Cerebral palsy
Misoprostol
(n = 19)
21%(4/19)
50%(7/14)
29% (4/14)
Controls
(n = 60)
26% (15/58)
16% (6/38)
3% (1/38)
P
0.768
0.026
0.015
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